Remove Medical Remove Trading Remove Valuation
article thumbnail

Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?

Cooley M&A

Despite market speculation around potential sales of publicly traded biotech firms fueled by shifting regulatory environments, capital constraints and strategic realignments relatively few large transactions actually took place. Similarly, Novo Holdings $16.5

M&A 64
article thumbnail

Using options to trade this beaten-down beer giant that Warren Buffett holds

CNBC: Investing

However, the current pessimism surrounding the stock appears overdone, possibly presenting a compelling valuation even as many stocks, net of the S & P 500's rally this past week to new all-time highs, are beginning to look stretched. STZ trades at a price-to-sales (P/S) ratio of approximately 3.5, The company's $1.2

Trading 67
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How Private Equity uses ‘Roll-up’ Strategies to Drive Investment Returns

OfficeHours

In a roll-up strategy, a private equity firm will attempt to consolidate a large number of smaller firms into a single, professionalized company with numerous benefits, including economies of scale and fixed cost leverage, valuation uplift (so-called “multiple arbitrage”), and acquisition expertise, among others.

article thumbnail

The Full Guide to Healthcare Private Equity, from Careers to Contradictions

Mergers and Inquisitions

The short answer to #1 is that healthcare private equity firms operate in specific verticals with stable-ish cash flows, such as healthcare services, nursing facilities, medical devices, equipment, and healthcare IT. Areas like healthcare services and medical devices are fairly generalist and follow standard accounting and valuation.

article thumbnail

The Sky Definitely Is Not Falling…At Least Not Yet

Sica Fletcher

No one really knows how the pandemic will play out from a medical, economic, political, and societal perspective. This reflected the impact of valuations on deal flow and an increasing imbalance of potential sellers and buyers. We face a future of uncertainty. Dry powder reached $1.4 trillion as of December 2019, a record high.

article thumbnail

Cooley’s 2019 Life Sciences M&A Year in Review

Cooley M&A

A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2 Year of the Life Sciences Mega-Deals. billion acquisition of The Medicines Company.

M&A 40
article thumbnail

Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024

Cooley M&A

Valuation disconnects persist In the post-COVID era, the life sciences market has experienced an increased polarization of successful and distressed companies, with sharp contrasts in liquidity and investment interest as buyers focus on de-risked assets. The results Add all those things together and what do we get?

M&A 52